Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Prof Alex Molassiotis
+44 (0)161 306 7830
alex.molasiotis@polyu.edu.hk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - The characterization and treatment of cough in lung cancer
Back

The characterization and treatment of cough in lung cancer

Not Recruiting

Open to: All Genders

Age: Adult

Manchester Manchester

Medical Conditions

Cough in Lung Cancer

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

05 Oct 2011 01 Jun 2012

Publications

2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30321508 results (added 24/01/2019)

Observational

Intervention Type : Other
Intervention Description : Day 0 Groups A and B: Case Report Form will be completed by investigator, Brief Reflux Inventory, Visual Analogue Scale (VAS), Manchester Cough in Lung Cancer Scale questionnaire and Quality of LIfe (QOL) questionnaire. Spirometry will be performed on all patients. In Group B, the ambulatory cough monitor will be fitted.

Day 1 Group B: Ambulatory cough monitor removed.

Day 30 (+/- 7 days) Groups A and B: A telephone assessment to conduct the Manchester Cough in Lung Cancer Scale questionnaire and to instruct the patient to complete a VAS on the day at home. Patients will have been given a VAS on Day 0 to complete on day 30 at home. Case Report Form re: antitussives, opiates or angiotensin converting enzymes (ACE) inhibitors and current anticancer treatment will be completed by the study investigator.

Day 60 (+/ 7 days) Groups A and B: A VAS, Manchester Cough in Lung Cancer Scale questionnaire, investigator and QOL questionnaire will be completed. Case Report Form re: treatment data will be completed by the study investigator. Spirometry will be performed on all patients. A cough monitor will be refitted in group B.

Day 61 Group B : Ambulatory cough monitor removed.

This coincides with routine treatment appointments to minimise extra patient visits.




You can take part if:



You may not be able to take part if:


Patients unable to complete self-reporting questionnaires


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Christie NHS Foundation Trust
    Wimlsow Road
    Manchester
    M20 4BX
  • University Hospitals of South Manchester NHS Trust
    Southmoor Road
    Manchester
    M23 9LT

This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.

Prof Alex Molassiotis
+44 (0)161 306 7830
alex.molasiotis@polyu.edu.hk



The study is sponsored by The Christie NHS Foundation Trust (UK) and funded by National Institute for Health Research (NIHR) (UK) (ref: DRF-2010-03-55).



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN72828211
Last updated 26 October 2022

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top